RT Journal Article
SR Electronic
T1 Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.30.21259796
DO 10.1101/2021.06.30.21259796
A1 Harrington, Whitney E.
A1 Jiang, Yonghou
A1 Duffy, Fergal
A1 Hadlock, Jennifer
A1 Raappana, Andrew
A1 Styrchak, Sheila
A1 Beck, Ingrid
A1 Chour, William
A1 Houck, John
A1 Duvvuri, Venkata
A1 Yeung, Winnie
A1 Haglund, Micaela
A1 Wallner, Jackson
A1 Wallick, Julie A.
A1 Hardy, Samantha
A1 Oldroyd, Alyssa
A1 Ko, Daisy
A1 Gervassi, Ana
A1 Murray, Kim M.
A1 Kaplan, Henry
A1 Aitchison, John D.
A1 Heath, James R.
A1 Sather, D. Noah
A1 Goldman, Jason D.
A1 Frenkel, Lisa
YR 2021
UL http://medrxiv.org/content/early/2021/07/05/2021.06.30.21259796.abstract
AB BACKGROUND Coronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (AT1R-Ab).METHODS We compared prevalence and levels of AT1R-Ab in COVID-19 cases with mild or severe disease to age and sex matched negative controls.RESULTS There were no significant differences between cases and controls. However, there were trends toward a higher proportion with AT1R-Ab positivity among severe cases versus controls (32% vs. 11%, p=0.1) and higher levels in those with mild COVID-19 compared to controls (median 9.5U/mL vs. 5.9U/mL, p=0.06).CONCLUSIONS These findings suggest that AT1R-Ab are not consistently associated with COVID-19 but do not exclude a contribution to endothelial pathology in a subset of people.Competing Interest StatementJ.D.G. declared research support from Gilead, Lilly, and Regeneron, and Monogram Biosciences and served on advisory board for Gilead. The other authors declare no conflicts of interest.Funding StatementThis work was supported by Seattle Childrens Research Institute [to LF, WEH, NS, and JDA]; the National Institute of Allergy and Infectious Diseases [K08 AI135072 to WEH]; the Burroughs Wellcome Fund [CAMS 1017213 to WEH]; the Biomedical Advanced Research and Development Authority [HHSO10201600031C to JRH]; and the Swedish Medical Center Foundation [to JDG]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mild COVID-19 cases were from the Seattle Childrens SARS-CoV-2 Recovered Cohort and the Seattle Childrens SARS-CoV-2 Prospective Cohort both approved by Seattle Childrens Hospital IRB. Severe COVID-19 cases were participants in the Swedish-Institute for Systems Biology Novel Coronavirus (INCOV) Biobank, approved by Providence St. Joseph Health IRB. Healthy controls were derived from the Childrens SARS-CoV-2 Prospective Cohort. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request from Dr. Harrington